Skip to main content

Table 3 Hazard ratio of death, based on patient characteristics and treatments received

From: Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy

Variable Contrast HR (95% CI) P value
Multivariate landmark analysis (n = 642)
Regimen AT + HER2 vs. A + T 0.90 (0.37–2.20) 0.82
PC vs. A + T 1.28 (0.55–2.98) 0.56
A no T vs. A + T 1.25 (0.47–3.35) 0.66
Age 21–40 vs. 41–60 2.00 (1.05–3.82) 0.036
> 60 vs. 41–60 2.04 (1.01–4.15) 0.048
Postmenopausal Yes vs. no 0.82 (0.43–1.59) 0.57
Stage IIB vs. IIA 1.15 (0.60–2.23) 0.67
IIIA vs. IIA 0.73 (0.24–2.15) 0.56
IIIB vs. IIA 2.06 (0.87–4.88) 0.099
IIIC vs. IIA 2.26 (1.11–4.61) 0.024
Grade III vs. I/II 0.67 (0.35–1.28) 0.22
Subtype HER2-amplified vs. TN 0.56 (0.25–1.28) 0.17
HR vs. TN 1.00 (0.46–2.22) 0.99
Adjuvant chemotherapy Yes vs. no 1.33 (0.64–2.77) 0.45
Adjuvant hormone therapy Yes vs. no 0.75 (0.39–1.45) 0.40
Adjuvant radiation treatment Yes vs. no 0.65 (0.34–1.22) 0.18
  1. Abbreviations: A no T Adriamycin-based therapy alone, A + T Adriamycin plus taxane, AT + HER2 HER2-targeted therapy, PC Provider choice, HR Hormone receptor, TN Triple-negative breast cancer
  2. Italicized values are statistically significant
\